JP6223451B2 - がんの診断及び治療方法 - Google Patents

がんの診断及び治療方法 Download PDF

Info

Publication number
JP6223451B2
JP6223451B2 JP2015530089A JP2015530089A JP6223451B2 JP 6223451 B2 JP6223451 B2 JP 6223451B2 JP 2015530089 A JP2015530089 A JP 2015530089A JP 2015530089 A JP2015530089 A JP 2015530089A JP 6223451 B2 JP6223451 B2 JP 6223451B2
Authority
JP
Japan
Prior art keywords
ntrk1
gene fusion
mprip
mprip gene
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015530089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528295A5 (enExample
JP2015528295A (ja
Inventor
ロバート シー. ドーベル
ロバート シー. ドーベル
マリレイラ ヴァレッラ ガルシア
マリレイラ ヴァレッラ ガルシア
アン ティー. レ
アン ティー. レ
Original Assignee
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト, ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト filed Critical ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト
Publication of JP2015528295A publication Critical patent/JP2015528295A/ja
Publication of JP2015528295A5 publication Critical patent/JP2015528295A5/ja
Application granted granted Critical
Publication of JP6223451B2 publication Critical patent/JP6223451B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015530089A 2012-08-31 2013-08-30 がんの診断及び治療方法 Expired - Fee Related JP6223451B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261696002P 2012-08-31 2012-08-31
US61/696,002 2012-08-31
US201361827514P 2013-05-24 2013-05-24
US61/827,514 2013-05-24
PCT/US2013/057495 WO2014036387A2 (en) 2012-08-31 2013-08-30 Methods for diagnosis and treatment of cancer

Publications (3)

Publication Number Publication Date
JP2015528295A JP2015528295A (ja) 2015-09-28
JP2015528295A5 JP2015528295A5 (enExample) 2017-09-07
JP6223451B2 true JP6223451B2 (ja) 2017-11-01

Family

ID=50184648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015530089A Expired - Fee Related JP6223451B2 (ja) 2012-08-31 2013-08-30 がんの診断及び治療方法

Country Status (5)

Country Link
US (1) US20150218652A1 (enExample)
EP (1) EP2890815B1 (enExample)
JP (1) JP6223451B2 (enExample)
CA (1) CA2882759C (enExample)
WO (1) WO2014036387A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
ME03010B (me) 2008-10-22 2018-10-20 Array Biopharma Inc Jedinjenja supstituisanog pirazol0[1,5-]pirimidina као inhibitori trk kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL2918588T3 (pl) 2010-05-20 2017-10-31 Array Biopharma Inc Związki makrocykliczne jako inhibitory kinazy TRK
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2914621B1 (en) * 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
WO2015184443A1 (en) * 2014-05-30 2015-12-03 The Regents Of The University Of Colorado Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
TWI767858B (zh) 2014-11-16 2022-06-11 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
HK1255330A1 (zh) 2015-08-26 2019-08-16 缆图药品公司 适用於治疗与ntrk相关的病症的化合物和组合物
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
WO2017087778A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
DK3439662T3 (da) 2016-04-04 2024-09-02 Loxo Oncology Inc Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN111886006B (zh) 2018-01-31 2024-07-09 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
AU2019215081B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019319109A1 (en) * 2018-08-07 2021-02-25 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in cobination with anaplastic lymphoma kinase inhibitors
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
CN109988836B (zh) * 2019-03-18 2022-06-07 厦门艾德生物技术研究中心有限公司 一种检测ntrk融合的fish探针组及其应用
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
CN119970649A (zh) 2019-12-30 2025-05-13 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021173679A1 (en) * 2020-02-28 2021-09-02 Advanced Cell Diagnostics, Inc. Methods for detecting ntrk gene fusion using rna in situ hybridization
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122655B2 (en) * 2002-11-15 2006-10-17 New England Medical Center Hospital, Inc. Compositions involving M-RIP, and related methods for screening for anti-hypertensive agents, and uses thereof
PL2450437T3 (pl) * 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
EP2082035A4 (en) * 2006-09-15 2014-05-07 Univ Alberta AUTOMATED FISH ANALYSIS, CIRCULATION MICROFLUID CHIP AND METHOD FOR IMMOBILIZING CELLS ON A MICROFLUID CHIP
CA2725978A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
ES2700098T3 (es) * 2009-05-15 2019-02-14 Insight Genetics Inc Métodos relacionados con las fusiones de ALK para diagnosticar el cáncer
EP2499486A4 (en) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
WO2013059740A1 (en) * 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2914621B1 (en) * 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof

Also Published As

Publication number Publication date
EP2890815A4 (en) 2016-05-11
WO2014036387A2 (en) 2014-03-06
US20150218652A1 (en) 2015-08-06
CA2882759A1 (en) 2014-03-06
WO2014036387A3 (en) 2014-05-08
EP2890815A2 (en) 2015-07-08
JP2015528295A (ja) 2015-09-28
CA2882759C (en) 2018-11-20
EP2890815B1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
JP6223451B2 (ja) がんの診断及び治療方法
US20220213553A1 (en) Prkc fusions
US20220205045A1 (en) Raf1 fusions
US20190389969A1 (en) Ntrk2 fusions
US9216172B2 (en) Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
JP7037836B2 (ja) タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途
JP6534930B2 (ja) Ntrk3融合体の検出法
US20170114415A1 (en) Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
US20170114417A1 (en) Pkn1 fusions
US20170211149A1 (en) Fgr fusions
US9109259B2 (en) Detection method for novel ROS1 fusions
JPWO2015064621A1 (ja) 新規融合体及びその検出法
JP2006523456A (ja) 分子細胞遺伝学的方法を用いる癌連鎖遺伝子および治療標的の確認
Zhang et al. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities
JP2009050189A (ja) 抗癌剤の有効性予測方法
JP7015171B2 (ja) 新規融合体及びその検出法
JP2003528630A (ja) ヒト遺伝子および発現産物
JP5467256B2 (ja) 消化器癌検出用血清腫瘍マーカー、消化器癌検出キット、および消化器癌検出方法
WO2016018116A1 (ko) 상피세포 성장인자 수용체 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
KR20180132376A (ko) 대장암 진단 마커로서의 신규 folr2 융합유전자 및 이의 용도
BG67180B1 (bg) Метод и кит за откриване на онкофузионен протеин

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150403

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170425

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171003

R150 Certificate of patent or registration of utility model

Ref document number: 6223451

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees